A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07645248. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, 2-way Crossover, Multicenter Study to Evaluate the Safety of Test Propellant HFA-152a and Reference Propellant HFA-134a When Administered Via Metered Dose Inhalers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
Study identification
- NCT ID
- NCT07645248
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 110 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2026 (Actual)
- Primary completion
- Dec 28, 2026 (Estimated)
- Completion
- Dec 28, 2026 (Estimated)
- Last update posted
- Nov 5, 2026
2026
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Aventura | Florida | 33180 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33155 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33173-3484 | Recruiting |
| GSK Investigational Site | Naples | Florida | 34102 | Recruiting |
| GSK Investigational Site | Owensboro | Kentucky | 42301 | Recruiting |
| GSK Investigational Site | Columbia | Missouri | 65203 | Recruiting |
| GSK Investigational Site | Henderson | Nevada | 89052-5015 | Recruiting |
| GSK Investigational Site | Medford | Oregon | 97504 | Recruiting |
| GSK Investigational Site | Spartanburg | South Carolina | 29303-4225 | Recruiting |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | Recruiting |
| GSK Investigational Site | Cypress | Texas | 77429 | Recruiting |
| GSK Investigational Site | Tomball | Texas | 77375 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07645248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.